Cover Image
市場調查報告書

鼻結膜炎:開發中產品分析

Rhino-Conjunctivitis - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 363111
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
鼻結膜炎:開發中產品分析 Rhino-Conjunctivitis - Pipeline Review, H1 2016
出版日期: 2016年06月15日 內容資訊: 英文 90 Pages
簡介

本報告提供鼻結膜炎治療藥的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

鼻結膜炎概要

治療藥的開發

  • 開發中產品的概要

鼻結膜炎:企業開發中的治療藥

鼻結膜炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

鼻結膜炎:企業開發中的產品

鼻結膜炎治療藥的開發企業

  • ALK-Abello A/S
  • Allergy Therapeutics Plc
  • ASIT biotech s.a.
  • Bial - Portela & Ca, S.A.
  • Circassia Pharmaceuticals Plc
  • Faes Farma, S.A.
  • Griffin Discoveries BV
  • HAL Allergy BV
  • Immunomic Therapeutics, Inc.
  • Laboratorios LETI S.L.
  • Oxagen Limited
  • Roxall Medizin GmbH
  • Stallergenes SAS

鼻結膜炎:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

鼻結膜炎:暫停中的計劃

鼻結膜炎:中止開發的產品

鼻結膜炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8178IDB

Summary

Global Markets Direct's, 'Rhino-Conjunctivitis - Pipeline Review, H1 2016', provides an overview of the Rhino-Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rhino-Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rhino-Conjunctivitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Rhino-Conjunctivitis
  • The report reviews pipeline therapeutics for Rhino-Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Rhino-Conjunctivitis therapeutics and enlists all their major and minor projects
  • The report assesses Rhino-Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Rhino-Conjunctivitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Rhino-Conjunctivitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Rhino-Conjunctivitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Rhino-Conjunctivitis Overview
  • Therapeutics Development
    • Pipeline Products for Rhino-Conjunctivitis - Overview
  • Rhino-Conjunctivitis - Therapeutics under Development by Companies
  • Rhino-Conjunctivitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Rhino-Conjunctivitis - Products under Development by Companies
  • Rhino-Conjunctivitis - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Allergy Therapeutics Plc
    • ASIT biotech s.a.
    • Bial - Portela & Ca, S.A.
    • Circassia Pharmaceuticals Plc
    • Faes Farma, S.A.
    • Griffin Discoveries BV
    • HAL Allergy BV
    • Immunomic Therapeutics, Inc.
    • Laboratorios LETI S.L.
    • Oxagen Limited
    • Roxall Medizin GmbH
    • Stallergenes SAS
  • Rhino-Conjunctivitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Allergic Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Birch Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Cupressus Arizonica Pollen Induced Allergic Rhino-Conjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for House Dust Mites Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergen for Salsola Kali Pollen Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Allergovac - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-4070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bilastine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • clustoid wiesenlieschgras - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gp-ASIT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OC-000459 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OC-2417 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pollinex Quattro Grass - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Asthma and Ragweed-Induced Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rhino-Conjunctivitis - Dormant Projects
  • Rhino-Conjunctivitis - Discontinued Products
  • Rhino-Conjunctivitis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 13, 2014: Circassia Announces Results from House Dust Mite Allergy Treatment Phase IIb Two-Year Follow-up Study
      • Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen
      • May 18, 2014: BioTech Tools will be present at the EAACI congress
      • Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology
      • Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics
      • Mar 20, 2012: HAL Allergy Completes Patient Enrollment For Phase II Trial With PURETHAL Mites
      • Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA
      • Oct 31, 2011: HAL Allergy Includes First Patient In Phase II PURETHAL Mites Study
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Rhino-Conjunctivitis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Rhino-Conjunctivitis - Pipeline by ALK-Abello A/S, H1 2016
  • Rhino-Conjunctivitis - Pipeline by Allergy Therapeutics Plc, H1 2016
  • Rhino-Conjunctivitis - Pipeline by ASIT biotech s.a., H1 2016
  • Rhino-Conjunctivitis - Pipeline by Bial - Portela & Ca, S.A., H1 2016
  • Rhino-Conjunctivitis - Pipeline by Circassia Pharmaceuticals Plc, H1 2016
  • Rhino-Conjunctivitis - Pipeline by Faes Farma, S.A., H1 2016
  • Rhino-Conjunctivitis - Pipeline by Griffin Discoveries BV, H1 2016
  • Rhino-Conjunctivitis - Pipeline by HAL Allergy BV, H1 2016
  • Rhino-Conjunctivitis - Pipeline by Immunomic Therapeutics, Inc., H1 2016
  • Rhino-Conjunctivitis - Pipeline by Laboratorios LETI S.L., H1 2016
  • Rhino-Conjunctivitis - Pipeline by Oxagen Limited, H1 2016
  • Rhino-Conjunctivitis - Pipeline by Roxall Medizin GmbH, H1 2016
  • Rhino-Conjunctivitis - Pipeline by Stallergenes SAS, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Rhino-Conjunctivitis - Dormant Projects, H1 2016
  • Rhino-Conjunctivitis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Rhino-Conjunctivitis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top